Unibest

UB388

TargetsAR
IndicationsMetastatic castration-resistant prostate cancer; Prostate cancer
ClinicalCN - I
TherapeuticsOncology
ModalitiesSmall Molecule

Exclusive Summary

  • • A Potential Best-in-class AR degrader.
  • • Capable of degrading AR gene amplification and drug-resistant mutations in the AR-LBD domain, including the L702H mutation.
  • • In vitro and in vivo activity is significantly superior to that of ARV766.

我们能如何帮助您?

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →